Figure 4.
Survival curves of 62 patients with MCL experiencing late POD divided according to TP53 mutational status at lymphoma diagnosis. (A) PFS from time of second-line therapy (PFS-2) of TP53 wild-type (WT; median, 25 months) vs mutated (median, 19 months). (B) Overall survival from time of second-line therapy (OS-2) of TP53 WT (median not reached) vs mutated (median, 24 months).

Survival curves of 62 patients with MCL experiencing late POD divided according to TP53 mutational status at lymphoma diagnosis. (A) PFS from time of second-line therapy (PFS-2) of TP53 wild-type (WT; median, 25 months) vs mutated (median, 19 months). (B) Overall survival from time of second-line therapy (OS-2) of TP53 WT (median not reached) vs mutated (median, 24 months).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal